A specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission and the spread of COVID-19, is more infectious in cell culture. The variant in question, D614G, makes a small but effective change in the virus’s “Spike” protein, which the virus uses to enter human cells. The new variant has become the dominant strain across the globe, but it does not appear to cause more severe disease.
Lead contiguous overlapping peptide candidate against birch pollen allergy is poised for Phase II studies.
Firms aim to bolster ProteoTech's alpha-synuclein program.
Deal grows buyer's vaccine portfolio as seller prepares to spin out biopharma business as part of planned split.
Chinese firm aims to develop antibodies, NCEs and naturally derived drugs against ER-a36 variant for multiple diseases.
Blocking receptor with drugs or scents might be new prostate cancer treatment
Firms' existing deal for Phase III-stage CKD anemia drug in U.S. broadened to Europe, Canada, China, Russia, Australia, and the Middle East. Akebia will receive $73 million upfront, $135 million in development funding, and up to $657 million in milestones.
Integrin inhibitor is being prepared for proof-of-concept clinical trials.
Some kids suffer repeated bouts with step throat and tonsillitis, whereas other kids seem relatively immune. What accounts for the differences in susceptibility? Unfortunately,...